Mineralys Therapeutics, Inc.· MLYS

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

RADNOR, Pa., July 27, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that (1) on July 17, 2026, the Compensation Committee of Mineralys' Board of Directors (the Compensation Committee) granted an inducement stock option award covering 14,880 shares and an inducement restricted stock unit award covering 11,160 shares of Mineralys common stock to a new non-executive employee, and (2) on July 20, 2026, the Compensation Committee granted an inducement stock option award covering 27,920 shares and an inducement restricted stock unit award covering 20,940 shares of Mineralys common stock to another new non-executive employees.